Kye Pharmaceuticals Inc. announced its partnership with Hyloris Pharmaceuticals SA ("Hyloris"), a Belgium-based developer, manufacturer and global supplier of a novel, prescription, oral solution form of atomoxetine. Through this partnership, Kye becomes the exclusive Canadian rights holder for the Atomoxetine Oral Solution developed by Hyloris. Under the terms of the agreement, Kye is responsible for the registration and commercialization of this product in Canada.

Atomoxetine Oral Solution may be indicated for the treatment of attention Deficit/Hyperactivity Disorder (ADHD) in children 6 years of age and over, adolescents, and adults. Atomoxetine Oral Solution can provide an easier to swallow, more appropriate formulation for patients with dysphagia (swallowing difficulties) or when requiring dosage titration, which is a key concern in children and some adults with ADHD.